University of SaskatchewanHARVEST
  • Login
  • Submit Your Work
  • About
    • About HARVEST
    • Guidelines
    • Browse
      • All of HARVEST
      • Communities & Collections
      • By Issue Date
      • Authors
      • Titles
      • Subjects
      • This Collection
      • By Issue Date
      • Authors
      • Titles
      • Subjects
    • My Account
      • Login
      JavaScript is disabled for your browser. Some features of this site may not work without it.
      View Item 
      • HARVEST
      • Electronic Theses and Dissertations
      • Graduate Theses and Dissertations
      • View Item
      • HARVEST
      • Electronic Theses and Dissertations
      • Graduate Theses and Dissertations
      • View Item

      CHARACTERIZING DRUG-RESISTANCE IN ADULTS WITH NEW-ONSET EPILEPSY

      Thumbnail
      View/Open
      DENTON-THESIS-2020.pdf (2.387Mb)
      Date
      2020-08-07
      Author
      Denton, Alyssa
      ORCID
      0000-0002-3322-5607
      Type
      Thesis
      Degree Level
      Masters
      Metadata
      Show full item record
      Abstract
      Background and objectives: There are very few studies reporting the factors involved in or the rate of drug-resistant epilepsy (DRE) in adults with new-onset epilepsy (NOE). This prospective cohort study characterizes DRE and risk factors in a pure adult cohort with NOE or newly diagnosed epilepsy (NDE). There are very few studies reporting the factors involved in or the rate of DRE in adults with NO and NDE. Methods: Patients were selected from a prospective cohort followed between 2011 and 2018 from the Single Seizure Clinic (SSC) in Saskatoon, SK. The SSC sees patients who experience their first seizure and approximately 30% are diagnosed with epilepsy. We identified the following variables and outcomes in the cohort: age, gender, epilepsy type, seizure onset, etiology, epilepsy syndromes, EEG and imaging outcomes, and the rates of DRE. Inclusion criteria included patients with NO and NDE, age 18 years or older at time of diagnosis, and a minimum 1 year of follow‐up. Results: Ninety-five patients were included, 46 females and 49 males. Median age of onset was 33 years. Of those, 20.0% developed DRE between 2011-2018. Average time between onset and DRE diagnosis was 2.32 years. Bivariate analysis identified age, gender, and etiology as important risk factors for DRE, however these variables failed to be significant in the multivariate model. Discussion: A lower percentage of DRE was identified in this cohort of adults compared to any other published study at present. The majority of patients to develop DRE were diagnosed in the first year of follow up, showing the importance of early characterization and treatment. Similarly, a younger age of onset was shown to be a substantial indicator of the prognosis. Despite a small cohort and insignificant statistical outcomes, our findings might guide the directions of future research in this topic. Significance: The specificity of the cohort along with the outcomes identified in this study contribute valuable information about NOE in adults and the development of DRE. This study has laid the groundwork for not only a larger cohort study to be implemented in the future, but also several other studies to evaluate potential predictors such as specific imaging results as a risk factor for DRE and quality of life assessment through follow-up related to DRE risk.
      Degree
      Master of Science (M.Sc.)
      Department
      Medicine
      Program
      Health Sciences
      Supervisor
      Tellez-Zenteno, Jose
      Committee
      Pena-Sanchez, Juan-Nicolas; Kirk, Andrew; Thorpe, Lilian; Camfield, Peter
      Copyright Date
      June 2020
      URI
      http://hdl.handle.net/10388/12955
      Subject
      epilepsy
      drug-resistance
      Collections
      • Graduate Theses and Dissertations
      University of Saskatchewan

      University Library

      The University of Saskatchewan's main campus is situated on Treaty 6 Territory and the Homeland of the Métis.

      © University of Saskatchewan
      Contact Us | Disclaimer | Privacy